Sanofi announces top-line results for cardiovascular outcomes study of Lyxumia® (lixisenatide)
19 March 2015 | By Victoria White
Sanofi announce top-line results of the Phase IIIb ELIXA cardiovascular outcomes study, comparing lixisenatide to placebo in adults with type 2 diabetes...





























